D Cecilia1, E Jódar, C Fernández, C Resines, F Hawkins. 1. Traumatology and Orthopedic Surgery, University Hospital 12 de Octubre, Avda de Andalucía km 5.4, Madrid 28041, Spain. dacecilia@hotmail.com
Abstract
SUMMARY: One year of once weekly alendronate, when given shortly after the surgical repair of a hip fracture, produces reductions in bone markers and increases proximal femoral bone density. The therapy was well tolerated. INTRODUCTION: Hip fracture is the most devastating type of osteoporotic fracture and increases notably the risk of subsequent fractures. The aim of this paper was to evaluate the effects of 1 year therapy with a weekly dose of alendronate in the bone mineral density and bone markers in elderly patients after low trauma hip fracture repair. METHODS:Two hundred thirty-nine patients (81 +/- 7 years; 79.8% women) were randomized to be treated either with calcium (500 mg/daily) and vitamin D(3) (400 IU/daily; Ca-Vit D group) or with alendronate (ALN, 70 mg/week) plus calcium and vitaminD(3) (500 mg/daily and 400 IU/daily, respectively; ALN + Ca-Vit D group). RESULTS:One hundred forty-seven (61.5%) patients completed the trial. Alendronate increased proximal femoral bone mineral density (BMD) in the intention-to-treat analysis (mean difference (95% confidence interval); total hip 2.57% (0.67; 4.47); trochanteric 2.96% (0.71; 5.20), intertrochanteric 2.32% (0.36; 4.29)), but the differences were not significant in the BMD of the femoral neck (0.47%; (-2.03; 2.96) and the lumbar spine (0.69%; (-0.86; 2.23)). Bone turnover markers decreased during alendronate treatment. CONCLUSION: The present study demonstrates for the first time the anti-resorptive efficacy of alendronate given immediately after surgical repair in an elderly population with recent hip fracture. This effect should positively affect the rate of subsequent fractures.
RCT Entities:
SUMMARY: One year of once weekly alendronate, when given shortly after the surgical repair of a hip fracture, produces reductions in bone markers and increases proximal femoral bone density. The therapy was well tolerated. INTRODUCTION:Hip fracture is the most devastating type of osteoporotic fracture and increases notably the risk of subsequent fractures. The aim of this paper was to evaluate the effects of 1 year therapy with a weekly dose of alendronate in the bone mineral density and bone markers in elderly patients after low trauma hip fracture repair. METHODS: Two hundred thirty-nine patients (81 +/- 7 years; 79.8% women) were randomized to be treated either with calcium (500 mg/daily) and vitamin D(3) (400 IU/daily; Ca-Vit D group) or with alendronate (ALN, 70 mg/week) plus calcium and vitamin D(3) (500 mg/daily and 400 IU/daily, respectively; ALN + Ca-Vit D group). RESULTS: One hundred forty-seven (61.5%) patients completed the trial. Alendronate increased proximal femoral bone mineral density (BMD) in the intention-to-treat analysis (mean difference (95% confidence interval); total hip 2.57% (0.67; 4.47); trochanteric 2.96% (0.71; 5.20), intertrochanteric 2.32% (0.36; 4.29)), but the differences were not significant in the BMD of the femoral neck (0.47%; (-2.03; 2.96) and the lumbar spine (0.69%; (-0.86; 2.23)). Bone turnover markers decreased during alendronate treatment. CONCLUSION: The present study demonstrates for the first time the anti-resorptive efficacy of alendronate given immediately after surgical repair in an elderly population with recent hip fracture. This effect should positively affect the rate of subsequent fractures.
Authors: T Schnitzer; H G Bone; G Crepaldi; S Adami; M McClung; D Kiel; D Felsenberg; R R Recker; R P Tonino; C Roux; A Pinchera; A J Foldes; S L Greenspan; M A Levine; R Emkey; A C Santora; A Kaur; D E Thompson; J Yates; J J Orloff Journal: Aging (Milano) Date: 2000-02
Authors: Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman Journal: Mayo Clin Proc Date: 2006-08 Impact factor: 7.616
Authors: Sarah D Berry; Elizabeth J Samelson; Marian T Hannan; Robert R McLean; Mei Lu; L Adrienne Cupples; Michele L Shaffer; Alexa L Beiser; Margaret Kelly-Hayes; Douglas P Kiel Journal: Arch Intern Med Date: 2007-10-08
Authors: Frederick Hooven; Stephen H Gehlbach; Penelope Pekow; Elizabeth Bertone; Evan Benjamin Journal: Osteoporos Int Date: 2004-06-17 Impact factor: 4.507
Authors: Cathleen Colón-Emeric; Maragatha Kuchibhatla; Carl Pieper; William Hawkes; Lisa Fredman; Jay Magaziner; Sheryl Zimmerman; Kenneth W Lyles Journal: Osteoporos Int Date: 2003-10-03 Impact factor: 4.507